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IntroductIon
Gene therapy holds the significance of correcting genetic defects, 
and there are many nucleic acid-based therapeutic strategies that 
can be used for gene therapy against cancer, including antisense 
and RNA interference (RNAi) mechanisms. Antisense oligonucle-
otides are typically 15–30 nucleotides long and block production 
of the disease-causing protein after complementarily hybridiz-
ing to their target messenger RNA (mRNA) and degrading the 
mRNA by activating RNaseH. RNAi is a separate process in which 
a specific mRNA is targeted for degradation in order to inhibit 
the synthesis of its encoded protein. Two types of small RNA 
molecules—microRNA (miRNA) and small interfering RNA 
(siRNA)—are central to the RNAi function. After delivery into 
the cytoplasm, the antisense strand of RNAi molecules recruits 
the corresponding mRNA in a sequence-specific manner to the 
RNA-induced silencing complex, which is followed by cleavage 
of the target mRNA, resulting in gene silencing. Both antisense 
oligonucleotides and RNAi-based therapy target mRNA to inhibit 
transcription of an overexpressing endogenous gene or a cancer-
causing oncogene,1 resulting in selectively inhibiting the expres-
sion of an unwanted protein (downregulation or loss of function). 
Plasmid DNA (pDNA) is also widely used to introduce a  normal 
wild-type transgene into specific cells of the host where the endog-
enous gene is underexpressing,1 resulting in expression of a defi-
cient protein (upregulation or gain of function).
Currently, three different kinds of gene delivery systems have 
been explored: modified naked siRNA, viral vectors, and nonviral 
vectors. Modified naked siRNAs have increased nuclease stability 
and gene silencing efficiency, as well as reduced immune responses 
and off-target effects, when compared to unmodified RNAs.2 Viral 
vectors have high gene transfection efficiency, but their residual 
viral elements can cause insertional mutagenesis and immuno-
logical problems. Nonviral vectors are constructed with biocom-
patible materials using innovative fabrication approaches, so that 
they can safely transport gene cargo in vivo, but their transfection 
efficiencies are not as high as viral vectors.
Therapeutic nucleic acids are potent in correcting genetic 
defects in cell and molecular levels, but in a real biological envi-
ronment, their lack of serum stability and rapid clearance greatly 
compromise their in vivo delivery, which retards gene therapy 
application in clinical setting. In this review, we will summarize 
the existing delivery barriers, highlight the strategies to overcome 
these hurdles, and introduce the current progress of nonviral 
 vectors constructed for cancer gene therapy.
challenges of gene delIvery
off-target effect
siRNAs are capable of reducing expression of nontarget genes due 
to interaction of the siRNA guide strand with a partially comple-
mentary site on an “off-target” mRNA.3 Careful selection of siRNA 
sequences to avoid off-target effects is an important issue, and can 
be minimized by avoiding certain sequence motifs. The design 
and selection of a specific siRNA may involve the consideration 
of internal repeated sequence, GC content, siRNA length, specific 
base preference, secondary structure, etc.4,5
Immune stimulation
Innate immune activation via RNA represents a significant unde-
sirable side effect due to the toxicities associated with excessive 
cytokine release6 and inflammatory syndromes after systemic 
administration. The inflammatory response is mediated by toll-like 
receptors (TLRs) TLR3, TLR7, TLR8, and TLR9, which are located 
in endosome compartments, and recognize unmethylated CpG 
DNA as well as various moieties in double-stranded RNA or their 
degraded products.7 A number of parameters affect how delivery 
vehicles potentiate immune stimulation. These include the chemi-
cal composition of the delivery vehicles, physical properties such as 
the size and charge of formulated materials, pharmacokinetics and 
biodistribution of formulated nucleic acids, and routes of admin-
istration.6 TLR-mediated recognition and concomitant immune 
stimulation can be inhibited by chemical modifications, such as 
introduction of 2′-O-methyl (2′OMe)-modified nucleotides.8
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delivery
The most important—and most difficult—challenge in gene ther-
apy is the issue of delivery. Not only must the therapy evade the 
reticuloendothelial system (RES) as it circulates after systemic 
administration, but it must also cross several barriers before it 
arrives in the cytoplasm or nucleus of its target cells.
Serum inactivation and enzyme degradation. Stabilization of 
RNA is regarded as a prerequisite for in vivo therapeutic applica-
tions, however, naked RNAs are rapidly degraded by nuclease in 
serum. Nuclease resistance can be enhanced by chemical modifi-
cation of RNAs. Because the 2′-hydroxyl group of the ribose ring 
is not necessary for potent gene silencing by siRNAs, the most 
widely used RNA modifications are on sugar moieties. Common 
modifications are 2′-fluoro, 2′-O-methyl, and 2′-amine conju-
gations.9 The locked nucleic acid conformation has a 2′-O, 4′-C 
methylene bridge in the sugar ring. Such locked nucleic acid mol-
ecules have the desirable features of increased nuclease  stability 
and silencing potency, as well as reduced off-target effects and im-
mune responses.7 Backbone modification by changing the inter-
nucleotide phosphate linkage, such as phosphorothioate (P = S) 
and boranophosphonate (P = B) modifications, can be placed 
in the RNA duplex at any desired position to enhance nuclease 
stability.9
Though modified RNAs are favorable for in vivo delivery 
when compared to naked RNAs, they lack specific tumor target-
ing and would be quickly excreted by the kidney upon systemic 
administration, so a large amount of modified RNAs are needed 
to attain desired therapeutic effects.10 Generally, modified RNAs 
are delivered by local injection, but the local route is only acces-
sible for certain cancers, such as skin cancer or head and neck 
cancer. Thus, most efforts have been concentrated on developing 
safe and effective nanoparticles for systemic gene delivery.
RES recognition. In order to condense negatively charged nu-
cleic acids into delivery vehicles, most nanoparticles contain 
polycations such as cationic polymers or lipids. The positive 
charge aids cellular uptake but also promotes nonspecific inter-
actions with nontarget cells and extracellular components such 
as serum proteins and extracellular matrix.11 Binding of plasma 
proteins is the primary mechanism for the RES to recognize cir-
culating nanoparticles,12 causing the major injected dose to go 
to RES organs, such as the liver, spleen, and bone marrow, im-
mediately after intravenous injection, with little accumulation 
in tumors.
The most common way to decrease nonspecific interactions 
is to shield the nanoparticle surface with hydrophilic, uncharged 
polymers such as polyethylene glycol (PEG). Surface PEG coat-
ing sterically hinders the interaction and binding of blood com-
ponents with the nanoparticle surface and prevents opsonization 
and recognition by phagocytes of the RES,13 resulting in prolonged 
nanoparticle circulation in the blood. The nanoparticle circulation 
half-life may vary by changes in PEG chain length, PEG density, 
surface coating, particle size, and surface charge of the underly-
ing nanostructure.14 PEGylated (aka stealth) nanoparticles with 
a reduced RES uptake and a prolonged circulation half-life are a 
prerequisite for enhanced tumor targeting.12
The EPR effect. Transport of macromolecules across the tumor 
endothelium is more efficient than that of normal endothe-
lium because of its leaky and discontinuous vascular structures 
(permeation) with poor lymphatic drainage (retention), which 
is  referred to as “enhanced permeability and retention (EPR) 
effect”.15 In other words, tumor endothelium allows the penetra-
tion of macromolecules and most nanoparticles. The EPR effect 
can be enhanced by PEGylation because the amount of blood 
that circulates through the tumor is usually far less than that of 
the RES organs, and only those nanoparticles that are not rapidly 
cleared from the circulation will have a chance to encounter the 
leaky tumor vasculature.12
Not all human tumors are equally leaky; for tumors with less 
leaky vasculatures, nanoparticles with small size (less than 30 nm) 
are desirable,13 but for most tumors, nanoparticles with a mean size 
around 100 nm are attractive for tumor targeting. Particles that are 
100 nm in size also allow easier surface modification with PEG 
arranged in a brush mode, a conformation that efficiently prevents 
serum opsonization. Particles larger than 400 nm can not easily 
enter the capillary gaps in the tumor vasculature, whereas par-
ticles smaller than 70 nm are able to access the parenchymal cells 
in the liver (i.e., hepatocytes) after crossing the liver blood ves-
sels (known as the sinusoidal space), since the sinusoidal  vessels 
contain fenestrae that have an average diameter of 100 nm.11 Small 
particles are also prone to renal excretion through the glomeruli 
in the kidney, and their large surface curvature presents difficul-
ties for PEG shielding.
Entrance into cells: the PEG dilemma. PEGylation may protect 
nanoparticles from protein agglomeration and macrophage cap-
ture, controlling their biodistribution and tumor accumulation, 
but the PEG coating prevents the formation of essential nonbi-
layer intermediates16 and inhibits fusion with the cell and/or the 
endosomal membrane, thus reducing the potential of nanoparti-
cle cellular uptake and cargo release from endosomes, decreasing 
silencing or transfection efficiency.
To solve this PEG dilemma, labile bonds can be introduced in 
the PEG chain, so that nanoparticles become unPEGylated upon 
reaching the target cells, leading to increased rates of membrane 
destabilization, transport of the loaded cargo inside the cells, and 
release from the endosome. pH-sensitive lipids composed of PEG, 
an acid-labile linker, and a hydrophobic tail can be used to con-
struct fusogenic liposomes,17 or one can conjugate PEG and poly-
cations with acid-sensitive linkers followed by compacting nucleic 
acids into pH-triggered deshielding lipoplexes/polyplexes.18 
Enzyme-sensitive linkers can also be applied to conjugate PEG 
and lipids, followed by entrapping nucleic acids in liposome-like 
vehicles, so that the PEG moiety can be cleaved off in tumor sites 
where the specific enzyme is widespread.19–22
Besides the external stimuli-triggered PEG shedding, conju-
gates of lipids and hydrophilic polymers are generally able to dif-
fuse off membranes depending on the strength of the anchorage or 
the anchor chain composition.22 When particles (liposomes or lip-
oplexes) are coated with sheddable stealth PEG-lipid,22 the sponta-
neous shedding of the PEG-lipid from particles  (de-PEGylation)12,23 
will continuously happen when particles circulate in blood, 
which eventually exposes the shielded cationic lipids and allows 
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membrane fusion for nanoparticle uptake and endosome release.12 
In this case, the shedding rate is a crucial parameter that has to 
be addressed when designing sheddable PEG coating. If shedding 
occurs too quickly, the unprotected carrier will be rapidly cleared 
from circulation by the RES. In other words, RES competes with 
tumor for the uptake of nanoparticles.12 However, if shedding is 
incomplete or occurs too slowly, the therapeutic efficacy of the 
loaded cargo might be compromised.
Targeting ligands are also frequently modified on the nano-
particle surface for enhanced cellular uptake by receptor-me-
diated endocytosis. Commonly used targeting ligands include 
aptamers,24 cell penetrating peptides,25 antibodies,26 peptides or 
proteins,27 and small molecule ligands.28 Huang et al.29 conju-
gated the LRP1 ligand angiopep-2 to a PAMAM dendrimer using 
bifunctional PEG, and complexed it with plasmid DNA (pORF-
TRAIL) to treat brain glioma. Significant apoptosis induction and 
prolonged survival time after systemic administration indicated 
that the angiopep-2 peptide could be exploited as a specific ligand 
to cross the blood–brain barrier and target glial tumors. Sonsoles 
Diez et al.30 constructed an asialoglycoprotein receptor-targeted 
lipopolymeric vector using the asialofetuin ligand for IL-12 gene 
transfer in hepatocellular carcinoma in vivo.
Endosome escape. The delivery of nonviral gene vehicles almost 
invariably involves endocytosis, and escaping from endosomes 
before they traffic into lysosomes is an essential step for nanovec-
tors to avoid enzymatic degradation.
Cationic lipid complexes can bind to anionic lipids on the 
endosome membrane and form neutral ion pairs. These ion-pairs 
destabilize the endosome membrane and promote de-assembly of 
the lipoplex through the formation of the inverted hexagonal (HII) 
phase,31 and finally release nucleic acids to cytoplasm.
Some protonable groups that are charged at acidic pH but less 
charged at neutral pH could be an alternative choice to designing 
ionizable cationic lipids that condense nucleic acids and promote 
endosome release.11,32,33 The rational design lies in the pKa of the 
ionizable cationic lipid and the abilities of these lipids to induce 
the hexagonal HII phase structure with anionic lipids of the endo-
somal membrane when protonated in the acidic endosome.
Acid-responsive mechanisms have been widely used to 
design delivery carriers in order to promote endosome release. 
Polymers and peptides with high buffer capacity between pH 7.2 
and 5.0, such as polyethylenimine (PEI),34 or peptides containing 
the cationic amino group lysine, arginine, and imidazole group 
histidine,35 could buffer the endosome. This would cause more 
protons to enter into the endosomes, followed by chloride ions, 
leading to increased osmotic pressure and endosome rupture, 
releasing payloads into cytoplasm. This process is called the “pro-
ton sponge effect”.
Stimuli other than pH have been used to destabilize endosome 
membranes as well. Lipid or polymer derivatives which are sensi-
tive to sulfhydryl reduction36–38 and enzymatic cleavage21,39 have 
been used to construct nonviral gene vectors. Upon exposure to 
the intracellular reducing agents or selective enzymes at the target 
sites, the vectors become destabilized and fuse with the endosome 
membrane, and finally release the entrapped cargo. Some fuso-
genic peptides can also be combined with nanoparticles to induce 
membrane fusion in endosomes through their structural changes 
in acidic conditions as compared to physiological pH.40,41
Li and Huang42 developed a lipid-calcium-phosphate nanopar-
ticle (LCP) for efficient siRNA delivery. The LCP entraps siRNA in 
a biodegradable nanosized calcium phosphate precipitate (CaP) 
core. The LCP de-assembles in endosomes due to the CaP core 
dissolving in acidic conditions, which increases the osmotic 
pressure, causing the endosome to swell and burst to release the 
entrapped siRNA.
Nuclear entry. The final target destination of antisense oligonu-
cleotides, siRNA/miRNA, and mRNA, is the cytoplasm, whereas 
pDNA must be transported into the nucleus for gene expres-
sion. Nuclear transport generally occurs through nuclear pore 
complexes, however, nucleic acid condensates are impermeable 
through nuclear pore complexes due to their large size.43 In di-
viding cells, the nuclear envelope disassembles during mitosis; 
pDNA transfection can only occur at this stage of the cell cycle 
due to elimination of the permeability barrier. The amount of 
DNA that reaches the nucleus is made lower due to the cytoplas-
mic nuclease that can degrade DNA, such that the majority of 
DNA that enters the cytoplasm never arrives in the nucleus. For 
nondividing cells, the mechanisms of DNA nuclear transport are 
of critical importance.
To facilitate nuclear targeting, many nuclear localization sig-
nal (NLS) peptides have been developed to allow DNA nuclear 
entry through nuclear pore complexes by active transport. NLSs 
are short clusters of amino acids that can bind to cytoplasmic 
receptors known as importins. NLS peptides can bind to DNA 
either through noncovalent electrostatic interaction or by cova-
lent attachment. The most well-known and popularly used NLS 
is from the large tumor antigen of simian virus 40 (SV40).44 Some 
DNA sequences themselves have nuclear import activity based on 
their ability to bind to cell-specific transcription factors, such as 
the SMGA promoter and flk-1 promoter.45
In summary, in order to elicit superior in vivo therapeutic 
response to correct genetic defects, the nonviral vector must be 
able to tightly condense and protect nucleic acids to avoid enzy-
matic degradation, accumulate at tumor sites with little RES 
uptake, target specific cells, disrupt the endosomal membrane and 
release the therapeutic cargo to cytoplasm, and translocate the 
DNA cargo to the nucleus.43 (Figure 1)
nonvIral vector desIgn for In ViVo gene 
delIvery
lipoplex/polyplex
Nucleic acids are easily complexed with cationic lipids (e.g., 
DOTAP), cationic polymers (e.g., PEI), biodegradable cationic 
polysaccharides (e.g., chitosan), and cationic polypeptides (e.g., 
polylysine, protamine), via electrostatic interactions. By chang-
ing the charge ratio associated with nucleic acids and condensing 
agents, the transfection efficiency of condensates can be opti-
mized.11 Cationic polymers and lipids have shown superior gene 
transfection efficiency, but they have dose-dependent toxicity upon 
systemic administration. Among cationic polymers, the polymer 
chain length and the presence or absence of hydroxyl groups 
play a role in polyplex size and charge in addition to transfection 
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efficiency and toxicity. The high gene transfection usually corre-
lates with the high cytotoxicity.46 Grandinetti et al.47 reported that 
direct interaction between (PEI-pDNA) polyplexes and mitochon-
dria during PEI transfection causes impaired mitochondrial func-
tion through membrane depolarization and could be the reason 
for high cytotoxicity in the PEI-based vehicles. This toxicity can be 
ameliorated by conjugation with biocompatible, hydrophilic poly-
mers such as PEG,48,49 and some pH and enzyme-sensitive linkers 
are widely used. For example, Walker et al. designed pH-triggered 
deshielding polyplexes to enhance endosome release, and Yin et 
al. entrapped RNA in poly (β-amine esters) complex nanoparticles 
that are degradable in the reductive environment due to the cleav-
age of disulfide bonds.18,50 Furthermore, some synthetic polymers 
have been optimized using combinatorial chemistry and library 
screening in order to mimic viral functional delivery domains, 
such as surface ligands for cell entry, evasion from endolysosomal 
compartment, and entry into the cytoplasm of target cells. Many 
defined, precise sequences have been found to perform potent 
pDNA and siRNA delivery by using solid-phase synthesis.51 Since 
different topologies of the defined synthetic polymer structures 
can influence the complexation and biological properties of trans-
fection agents, Schaffert et al.52 explored the gene delivery effi-
ciency and cytotoxicity of linear polycations with modifications 
in different areas and found that these changes could cause robust 
differences in biological function.
lipopolyplex
In order to increase serum stability, avoid RES uptake, and increase 
tumor accumulation, Li et al.53 designed a liposome-polycation-
DNA nanoparticle (LPD) for siRNA delivery. siRNAs were mixed 
with calf thymus DNA before being condensed with protamine. 
Protamine is a natural arginine-rich cationic polypeptide which is 
biocompatible, biodegradable, and nontoxic, so it is more desirable 
than synthetic polymers. The condensed particles were wrapped 
by cationic liposomes, followed by grafting PEG-lipid conjugate 
(DSPE-PEG) with or without a targeting ligand using a postin-
sertion method. The LPD can deliver a significant fraction of 
injected siRNA into the tumor after intravenous injection with lit-
tle RES uptake. siRNA formulated in the targeted LPD completely 
silenced oncogenes in tumors, induced tumor cell apoptosis, and 
achieved superior tumor growth inhibition.54,55 By adjusting the 
siRNA to protamine ratio, a positively charged LPD core can also 
be attained. LPD-II was formed by wrapping an anionic liposome 
composed of DOPA (dioleoylphosphatydic acid) around this LPD 
core, followed by grafting DSPE-PEG.56 Based on the LPD formu-




























figure 1 representative scheme of in vivo gene delivery barriers. EPR, enhanced permeability and retention; mRNA, messenger RNA; 
PEG,  polyethylene glycol; RES, reticuloendothelial system; RISC, RNA-induced silencing complex; siRNA, small interfering RNA.
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acid (or heparin) nanoparticle (LPH). A remarkable advantage for 
LPH is that it showed very little immunotoxicity in a wide dose 
range compared to LPD. Chen et al.58 used the scFv ligand tar-
geted LPH to effectively deliver siRNAs (c-Myc/MDM2/VEGF) 
and miRNA-34a to a B16F10 lung metastasis model. Figure 2 
shows the structure and preparation scheme of LPD (LPD-II)/
LPH nanoparticles.
mRNA can be loaded in lipopolyplexes (termed LPRs, lipid-
polymer-RNA) using the similar method of LPDs. Perche et al.59 
reported that MART-1 mRNA lipopolyplexes with mannosylated 
liposomes (Man11-LPR100) targeting dendritic cells can be used 
as an efficient system for anti-B16F10 melanoma mRNA-based 
vaccines. A great inhibition of B16F10 melanoma growth was 
obtained after mice were intravenously immunized with MART-1 
Man11-LPR100, indicating that tumor antigen mRNA-loaded 
Man11-LPR100 is an efficient system to induce an anticancer 
immune response. Although mRNA serves as a potential ther-
apy in various medical indications, like other nucleic acid mol-
ecules, its strong immunogenicity and limited stability hamper 
clinical applications. To solve these limitations, Kormann et al.60 
designed a combination of nucleotide modifications. They found 
that replacement of only 25% of uridine and cytidine with 2-thio-
uridine and 5-methyl-cytidine synergistically abrogated mRNA 
interaction with TLR3, TLR7, TLR8, and retinoid-inducible gene 
I, thus substantially decreasing activation of the innate immune 
system. High expression of therapeutic proteins were detected 
in mice after intramuscular administration of double-modified 
mRNA, as well as in a congenital surfactant protein B (SP-B) defi-
ciency disease model after two intratracheal doses of modified 
SP-B mRNA. Furthermore, entrapping modified mRNA in LPD 
nanoparticle has shown superior therapeutic effects in xenograft 
tumor models (unpublished data in Huang lab).
Although LPD nanoparticles are successful in the systemic 
delivery of siRNA, the delivered siRNA does not completely dis-
sociate from the nanoparticles, such that most of the encapsulated 
siRNA is not bioavailable. In order to solve the problem regarding 
the inefficient release of siRNA from LPD, Li et al.42 developed a 
LCP nanoparticle. The LPD’s DNA-protamine complex core was 
replaced by a biodegradable nanosized CaP precipitate prepared 
by water-in-oil microemulsions, and siRNA was entrapped in the 
CaP core. The rationale for the LCP design is that the CaP precipi-
tate in the LCP core would dissolve and de-assemble at low pH 
in the endosome, increase the osmotic pressure, and cause endo-
some swelling and bursting to release the entrapped siRNA. The 
LCP can be further optimized by changing the precipitate core 
and the coating lipids.
Harashima et al. developed a liposomal gene carrier known as 
multi-functional nano device (MEND) for systemic gene delivery. 
Similar to LPD, MEND consists of a nucleotide core condensed 
with polycations and covered with lipid membranes. The surface of 
the lipid envelope can be modified with various functional devices, 
such as PEG for prolonged circulation, specific ligands for target-
ing, or fusogenic peptides for endosomal escape.61 In order to avoid 
the PEG dilemma, an enzyme-cleavable PEG system, PEG-peptide-
DOPE conjugate, was used to modify MEND.21 In this strategy, the 
PEG is removed from MEND via the cleavage by a matrix metal-
loproteinase, which is specifically expressed in tumor tissues.
Harashima et al.40,41 further modified a fusogenic peptide GALA 
(WEAALAEALAEALAEHLAEALAEALEALAA) on MEND 
for the sake of promoting endosome release. The 30 amino acid 
GALA contains a glutamic acid-alanine-leucine-alanine sequence 
that is repeated four times. Since the carboxyl groups of glutamic 
acid are negatively charged at physiological pH, electric repulsion 
between these groups forces GALA to be a random coil structure. 
In contrast, at acidic endosomal pH, protonation of the carboxyl 
group side chains of the glutamic acids dissipates electric repul-
sion, so the GALA structure changes into an α-helix, a structure 
that tends to induce membrane fusion. To avoid the recognition by 
biomacromolecules in vivo, a shorter version of GALA (shGALA) 
was developed, which was masked by the PEG layer of the MEND. 
The shGALA-modified MEND showed significant gene silencing 
in the tumor and inhibition of tumor growth.
aptamer-sirna chimeras
Aptamers are three-dimensional single-chain nucleic acid mol-
ecules that bind to a specific target molecule with high affinity 
and specificity.62 They are selected from a combinatorial library 
of randomized sequences through repeated rounds of selection, 
known as “systematic evolution of ligands by exponential enrich-
ment” (SELEX),63 and the target molecules can be small molecules, 
nucleic acids, proteins, carbohydrates, whole cells, and even organ-
isms. Aptamers have high diversity and those possessing very high 
affinities to the target molecules can be isolated. In addition, they 
are relatively stable in storage and elicit little immunogenicity in 
therapeutic applications.
Most aptamer-siRNA targeted chimeras for cancer therapy 
are against prostate-specific membrane antigen (PSMA), a cell-
surface receptor overexpressed in prostate cancer cells and tumor 
vascular endothelium. McNamara et al.64 developed aptamer-
siRNA chimeric RNAs. The aptamer portion of the chimeras 
mediated binding to PSMA, whereas the siRNA portion targeted 













figure 2 the structure and preparation scheme of lPd (lPd-II)/
lPh nanoparticles. LPD, liposome-polycation-DNA; LPH, liposome-
polycation-hyaluronic acid (or heparin); pDNA, plasmid DNA; PEG, 
 polyethylene glycol; siRNA, small interfering RNA.
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effectively delivered siRNAs to LNCaP prostate cancer cells 
expressing PSMA, and triggered apoptosis and cell death both in 
cultured cells and in a prostrate tumor xenograft model.64 In order 
to enhance silencing activity and specificity of siRNA, Dassie et 
al.65 incorporated modifications, including adding 2-nucleotide 
3′-overhangs and optimizing the thermodynamic profile and 
structure of the duplex, which enabled more efficient processing 
of the siRNA guide strand and reduced the effective concentra-
tion of siRNA portion. The optimized chimeras resulted in pro-
nounced regression of PSMA-expressing tumors after systemic 
administration. Antitumor activity was further enhanced by graft-
ing a 20 kDa PEG moiety to the 5′-terminus of the RNA strand, 
which increased the chimeras’ circulating half-life and bioavail-
ability without affecting chimera targeting and silencing. The 
aptamer portion of the chimeras can also be truncated from 71 to 
39 nucleotides without loss of function, so that large-scale chemi-
cal synthesis can be facilitated. In principle, the aptamer-siRNA 
chimera approach can be applied to target reagents to many differ-
ent cell types, provided that a cell-specific receptor exists and that 
an aptamer against the receptor can be selected.65
local gene delIvery
Local delivery by external stimulations can avoid or delay RES 
uptake, reduce systemic toxicity, provide organ specificity, and 
help the delivery system reach the target cells. These environment-
sensitive nanoparticles have been designed to release their con-
tents based on the environmental changes leading to controlled 
drug release, such as temperature, light, ultrasound response, or 
magnetic stimulus.
Bubble liposomes by ultrasound exposure
Ultrasound technology provides an easy, safe, minimally invasive, 
and tissue-specific method for gene delivery into tumors.66 The 
bubble liposome is one of the most favorable ultrasound-aided 
delivery methods. Bubble liposomes entrap the ultrasound imaging 
gas perfluoropropane, exploiting the cavitation bubbles produced 
by the pressure oscillations of ultrasound. This not only tran-
siently enhances the permeability of a tissue or a cell membrane, 
reducing the thickness of the unstirred layer of the cell surface, 
and aiding DNA entry into cells,66 but also affects the intracellular 
vesicles and trafficking after ultrasound exposure, thus enhancing 
the escape of gene cargo from the endosome to the cytoplasm and 
further transfer to the nucleus.67 Negishi et al.67 have used bubble 
liposomes and ultrasound exposure to enhance targeted liposome-
mediated pDNA gene transfection, whereas Clumakova et al.68 
have demonstrated that their PLGA (poly(lactic-co-glycolic acid)) 
nanoparticle gene vector produced a significantly higher expres-
sion of the reporter gene in the tumor after a 5-minute ultrasonic 
treatment than that without ultrasound.
heat and irradiation
Au nanoparticles (AuNPs) possess vivid optical properties with 
strong optical resonances associated with their surface plasmons. 
The optical absorption of AuNPs can be tuned from 690 to 900 nm 
in the near-infrared spectral range by varying the relative geometry 
and size of the core and shell. The plasmon-based optical proper-
ties of AuNPs assist in the photothermal ablation of solid tumors, 
providing a light-triggered release of short DNA strands conju-
gated to the surface of AuNPs.18,69 Ni et al.70 delivered DNAPK 
short hairpin RNAs by PSMA-targeting A10-3 RNA aptamers that 
selectively sensitized PSMA-positive cells to ionizing radiation, so 
that the toxicities to normal tissues were reduced.
Magnetofection
Liposomal magnetofection potentiates gene transfection by 
applying a magnetic field. Wang et al.71 constructed magnetic 
lipoplexes, which are self-assembling complexes of cationic lip-
ids with plasmid DNA associated with superparamagnetic iron 
oxide nanoparticles. Liposomal magnetofection provided a three-
fold improvement in transgene expression over lipofection and 
knocked down the target protein in vitro. In vivo, the plasmid 
delivery efficiency into the tumor was significantly higher via 
liposomal magnetofection than lipofection.
conclusIon and PersPectIve
Various strategies have been developed to deliver gene cargos effi-
ciently into target cells by nonviral vectors, which have attracted 
much attention in recent years. Rationally designed nonviral vec-
tors have exhibited improved in vivo stability and pharmacokinet-
ics, little RES uptake, high tumor accumulation, target specificity, 
efficient endosome release, and nuclear transcription of the encap-
sulated therapeutic nucleic acids. Even so, we have no doubt that 
the development of safe, stable, effective, and tumor-specific 
nanoparticles for systemic administration remains an unmet goal 
for successful clinical applications of cancer gene therapeutics.
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